Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesEstrogen-progestagen menopausal hormone therapy and breast cancer: Does delay from menopause onset to treatment initiation influence risks?
Journal of Clinical Oncology, 09/15/09
Fournier A et al. – For some EP-MHT, the timing of treatment initiation transiently modulates the risk of breast cancer and that, when initiated close to menopause, even short durations of use are associated with an increased breast cancer risk. Estrogen + progesterone combinations might be an exception in this regard.
Methods- Between 1992 and 2005, 1,726 invasive breast cancers were identified among 53,310 postmenopausal women
- Mean duration of f/u, 8.1 years
- MHT never users as the reference
- Among recent users of EP-MHT, risk of breast cancer varied according to the timing of treatment initiation
- Variation was confined to short durations of use (2 years): the HR was 1.54 for short treatments initiated in the 3-year period following menopause onset and 1.00 for short treatments initiated later
- Pattern of risks was not observed in users of EP-MHT containing progesterone, among whom there was no significantly increased risk associated with short duration of use (HR was 0.87 for treatments initiated 3 years after menopause, and HR was 0.90 for treatments initiated later)
- Longer durations of EP-MHT use were generally associated with increases in breast cancer risk, whatever the gap time
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Hepatocyte Nuclear Factor-4–Independent Synthesis of Coagulation Factor VII in Breast Cancer Cells and Its Inhibition by Targeting Selective Histone Acetyltransferases
Molecular Cancer Research, 12/11/09Tamoxifen Inhibits TRPV6 Activity via Estrogen Receptor–Independent Pathways in TRPV6-Expressing MCF-7 Breast Cancer Cells
Molecular Cancer Research, 12/11/09Effects of distant metastasis and peripheral CA 15-3 on the induction of spontaneous T cell responses in breast cancer patients
Cancer Immunology, Immunotherapy, 12/11/09Today in Endocrine Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Poorly Differentiated Thyroid Carcinoma: 5 Years after the 2004 WHO Classification of Endocrine Tumours
Endocrine Pathology, 12/11/09Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer
Endocrine-Related Cancer, 12/10/09Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma
Endocrine-Related Cancer, 12/10/09Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical Benefit of Allogeneic Melanoma Cell Lysate–Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients
Clinical Cancer Research, 12/11/09Radiation Therapy for Rectal Cancer: Current Status and Future Directions
Cancer Control, 12/11/09Current Progress in Targeted Therapy for Colorectal Cancer
Cancer Control, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor